Evidence map›Paper›PMID 38895626›Full record

ArticleFrontiers in pharmacology2024

Anti-pulmonary fibrosis activity analysis of methyl rosmarinate obtained from

Li Ma, Chuntong Liu, Yuxiang Zhao, Mengke Liu, Yunyi Liu, Huachang Zhang, Shude Yang, Jing An, Yuheng Tian, Yinchuan Cao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Li Ma *Binzhou Medical University, Shandong, China.
Chuntong Liu *Binzhou Medical University, Shandong, China.
Yuxiang Zhao *Binzhou Medical University, Shandong, China.
Mengke LiuBinzhou Medical University, Shandong, China.
Yunyi LiuBinzhou Medical University, Shandong, China.
Huachang ZhangBinzhou Medical University, Shandong, China.
Shude YangDepartment of Edible Mushrooms, School of Agriculture, Ludong University, Shandong, China.
Jing AnDivision of Infectious Diseases and Global Health, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, United States.
Yuheng TianBinzhou Medical University, Shandong, China.
Yinchuan CaoBinzhou Medical University, Shandong, China.
Guiwu QuBinzhou Medical University, Shandong, China.
Shuling SongBinzhou Medical University, Shandong, China.
Qizhi CaoBinzhou Medical University, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis is a progressive, irreversible, chronic interstitial lung disease associated with high morbidity and mortality rates. Current clinical drugs, while effective, do not reverse or cure pulmonary fibrosis and have major side effects, there are urgent needs to develop new anti-pulmonary fibrosis medicine, and corresponding industrially scalable process as well.

Indexed as

MAPKMRpulmonary fibrosisRATGF-β/Smad

Identifiers

PMID38895626
PMCPMC11183283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.